Longevity & Cellular Health Research Peptides, Filed Under Routine Maintenance

The short version

Friend With Peptides is a reading desk for one corner of ageing research: the molecules studied as ordinary cellular maintenance rather than as treatment for a named disease. Three of them sit here — NAD+, MOTS-c and Epitalon.

What they have in common is that none of them was invented to do something new. Each one is a copy of, or a top-up for, something a healthy body already makes and uses every day. NAD+ is a coenzyme — a helper molecule an enzyme needs in order to work — that every cell uses and recycles constantly to turn food into usable energy ^[4]. MOTS-c is a small peptide written into mitochondrial DNA that muscle releases during exercise ^[11]. Epitalon is a four-amino-acid synthetic stand-in for an extract of the pineal gland, the tissue that helps set the sleep-wake rhythm ^[13].

That shared logic — top up the housekeeping, not the machinery — is what makes this group worth reading as a group. It is also what makes the evidence hard, because maintenance is slow and quiet, and slow quiet effects are the most difficult thing in medicine to measure. This desk sells nothing, recommends nothing, and cites everything.

What research peptides are, and what these three are not

Peptides are short chains of amino acids — the same units that build proteins, only far shorter. MOTS-c is one: sixteen amino acids, encoded inside the mitochondrial 12S ribosomal RNA gene ^[10]. Epitalon is a shorter one still — four amino acids, alanine-glutamate-aspartate-glycine, which is why the literature also calls it the AEDG peptide ^[13].

NAD+ is not a peptide at all, and this desk would rather say so than tidy the fact away. It is a dinucleotide: a redox coenzyme built from nicotinamide mononucleotide and adenosine monophosphate joined through two bridging phosphates. It sits here because the longevity conversation treats it as part of the same maintenance kit, and because the precursors sold to raise it — nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) — are the most heavily trialled compounds in this entire category ^[1].

What none of the three is: an approved medicine for ageing. NAD+ precursors are sold as dietary supplements, and the regulatory status of NMN in particular has been contested by the FDA on the grounds that it was investigated as a drug. MOTS-c and Epitalon are research chemicals with no approved human indication in the United States, the European Union or the United Kingdom. Every figure quoted on this site is the figure a study reported, in the population that study enrolled, and it appears here as a record of what was done — never as an instruction.

Why everyday upkeep is the hardest claim to test

The angle this desk takes is the daily-habit end of longevity research — energy, sleep and cellular upkeep. It is the friendliest-sounding corner of the field and the least forgiving one to study.

A drug for a disease has an obvious finish line: the tumour shrinks, the blood sugar falls, the infection clears. Maintenance has no such moment. If a molecule keeps mitochondria a little tidier for a decade, the effect on any given Tuesday is close to invisible, and the outcome that would actually prove it — a person ageing more slowly — takes longer to measure than most research funding lasts. So investigators substitute markers that can be read now: blood NAD+ concentration, insulin sensitivity, walking distance, telomere length in a dish. Those markers do move. Whether the person moves with them is the open question, and the 2025 Nature Metabolism review of the human NAD+ trial evidence said so plainly, concluding that human trials have shown limited efficacy and that data on tissue-specific NAD+ dynamics remain sparse ^[1].

There is a second problem, and it is the reason anecdote is labelled so carefully on this site. Upkeep effects are precisely the effects a person is worst at judging in themselves: sleep quality, daytime energy, a general sense of doing well. Those are also the effects that expectation moves most easily. Reading this category honestly means holding the mechanism and the evidence gap in view at the same time, without letting the first one stand in for the second.

How the three sit together

The three are not equally well studied, and the gap between them is the most useful thing on this site.

• NAD+ is the one with randomized human trials. Oral NMN at 300-900 mg per day for 60 days raised blood NAD+ dose-dependently in a multicentre double-blind trial in middle-aged adults, and improved walking distance and quality-of-life scores against placebo ^[2]. Ten weeks of oral NMN improved muscle insulin sensitivity in prediabetic, postmenopausal women ^[3]. Nicotinamide riboside raised whole-blood NAD+ by as much as 142% over eight weeks without a significant adverse-event difference from placebo ^[5]. Raising the marker is settled; what it buys is not.
• MOTS-c is the one the body already makes on its own during exercise ^[11]. It has the most elegant mechanism here — a peptide encoded in mitochondrial DNA that moves into the nucleus under metabolic stress and changes which genes get read ^[12] — and no human interventional trials at all. Its human data are association studies in patients, not experiments ^[9].
• Epitalon is the sleep-and-circadian one, and the one where enthusiasm most outruns evidence. Cell work shows it switching telomerase back on in human cells that had none ^[16], with a 2025 study finding the same effect in normal cells and a different, more troubling route in cancer lines ^[14]; rat pineal cells make more melatonin in its presence ^[15]. Its headline human result is a six-to-eight-year observational study rather than a randomized trial ^[17].

The comparison page sets the three side by side on mechanism, evidence maturity and what each is genuinely studied for.